Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder

Next Previous
X
Search
Trial Profile

A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilazodone (Primary) ; Citalopram
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories

    • Most Recent Events

    • 30 Mar 2018 Results (n=2218) of post-hoc analysis of four randomized trials assessing efficacy in subgroups of patients with major depressive disorder, were published in the International Clinical Psychopharmacology.
    • 04 Jun 2015 Results of post hoc analysis have been published in International clinical psychopharmacology.
    • 16 Mar 2015 Based on results of this trial the US FDA approved a supplemental NDA for a lower therapeutic dose of vilazodone (20mg), according to an Actavis media release; the approval fulfils a post-marketing commitment to identify the minimum effective dose.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top